Almac Group, the global contract pharmaceutical development and manufacturing organisation, has announced the appointment of Jonothan Cooil to Vice President of Engineering, Facilities and Health, Safety & Environment. He will report to Almac Group CEO, Alan Armstrong.
Craigavon, N.I., UK, 21 Aug 2018 – Almac Group, the global contract pharmaceutical development and manufacturing organisation, has announced the appointment of Jonothan Cooil to Vice President of Engineering, Facilities and Health, Safety & Environment. He will report to Almac Group CEO, Alan Armstrong.
Jon joins Almac with more than 20 years’ experience with some of the world’s leading companies. Most recently he was employed as Head of Engineering and HSE at a major global pharmaceutical company and was directly responsible for leading the expansion and regrowth of one of its sites. In addition, he led the corporate adoption of process safety in manufacture for the global organisation.
Previously, Jon was employed as Chief Engineer and Head of Process Safety at Warwick International, the world leader in the manufacture of Tetraacetylethylenediamine (TAED), where he was responsible for engineering and process safety on a 30 acre top tier Control of Major Accident Hazards (COMAH) chemical site.
Jon is a highly respected academic and has lectured at John Moores’ University as well as being the external examiner in the BEng and MEng engineering courses. He is also a certified 6 sigma black belt and a Total Productive Maintenance (TPM) champion.
Alan commented, “We are delighted to have Jon join the Almac leadership team. He has a proven track record of driving improvement and operational efficiency which is aligned to our global growth plans. His wealth of experience will be invaluable to our future success.”
About Almac Group
‘Partnering to Advance Human Health’
The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation that has organically grown over almost 50 years and now employs close to 5,000 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with additional operations in Europe, across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).
To keep up to date with our latest releases, follow us on Twitter and LinkedIn
